Metabolic reprogramming in atherosclerosis: Opposed interplay between the canonical WNT/β-catenin pathway and PPARγ.
Animals
Atherosclerosis
/ etiology
Biomarkers
Cellular Reprogramming
Disease Susceptibility
Endothelium
/ metabolism
Energy Metabolism
Extracellular Matrix
/ metabolism
Humans
Metabolic Networks and Pathways
PPAR gamma
/ metabolism
Protein Binding
Vascular Calcification
/ metabolism
Wnt Signaling Pathway
Aerobic glycolysis
Atherosclerosis
PPAR gamma
WNT pathway
Warburg effect
Journal
Journal of molecular and cellular cardiology
ISSN: 1095-8584
Titre abrégé: J Mol Cell Cardiol
Pays: England
ID NLM: 0262322
Informations de publication
Date de publication:
08 2019
08 2019
Historique:
received:
02
03
2019
revised:
27
05
2019
accepted:
29
05
2019
pubmed:
4
6
2019
medline:
26
6
2020
entrez:
3
6
2019
Statut:
ppublish
Résumé
Atherosclerosis, a chronic inflammatory and age-related disease, is a complex mechanism presenting a dysregulation of vessel structures. During this process, the canonical WNT/β-catenin pathway is increased whereas PPARγ is downregulated. The two systems act in an opposite manner. This paper reviews the opposing interplay of these systems and their metabolic-reprogramming pathway in atherosclerosis. Activation of the WNT/β-catenin pathway enhances the transcription of targets involved in inflammation, endothelial dysfunction, the proliferation of vascular smooth muscle cells, and vascular calcification. This complex mechanism, which is partly controlled by the WNT/β-catenin pathway, presents several metabolic dysfunctions. This phenomenon, called aerobic glycolysis (or the Warburg effect), consists of a shift in ATP production from mitochondrial oxidative phosphorylation to aerobic glycolysis, leading to the overproduction of intracellular lactate. This mechanism is partially due to the injury of mitochondrial respiration and an increase in the glycolytic pathway. In contrast, PPARγ agonists downregulate the WNT/β-catenin pathway. Therefore, the development of therapeutic targets, such as PPARγ agonists, for the treatment of atherosclerosis could be an interesting and innovative way of counteracting the canonical WNT pathway.
Identifiants
pubmed: 31153873
pii: S0022-2828(19)30111-7
doi: 10.1016/j.yjmcc.2019.05.024
pii:
doi:
Substances chimiques
Biomarkers
0
PPAR gamma
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
36-46Informations de copyright
Copyright © 2019 Elsevier Ltd. All rights reserved.